安全性认知:人乳头瘤病毒疫苗接种规划的最大敌人是什么?
本文综述了人乳头瘤病毒(HPV)疫苗的安全性证据与接种犹豫问题。目前已上市三种预防性疫苗(双价、四价、九价),上市前后研究(九价疫苗尚无上市后研究)确认其总体安全耐受,注射部位症状最常见、疼痛为最常报告局部症状,严重不良事件罕见且无疫苗相关死亡。心理、宗教文化及对不良事件的恐惧构成犹豫障碍,薄弱沟通策略与不实信息传播可致规划失败,日本2013年事件使大量女性仍面临HPV相关癌症风险;多组分对话式干预似最有效。
要点
- 已上市三种预防性HPV疫苗:双价16/18、四价6/11/16/18和九价6/11/16/18/31/33/45/52/58。
- 上市前后研究(九价疫苗尚无上市后研究)确认HPV疫苗总体安全耐受,注射部位症状最常见,疼痛为最常报告局部症状。
- 严重不良事件罕见且无疫苗相关死亡,但心理反应、宗教文化因素及对脱髓鞘疾病、复杂性区域疼痛综合征(CRPS)或体位性心动过速综合征(POTS)的恐惧构成犹豫障碍。
核心结论
- 上市前后研究确认HPV疫苗总体安全耐受,严重不良事件罕见且无疫苗相关死亡,但接种犹豫仍是提高覆盖率的障碍。
- 薄弱沟通策略与媒体网站不实信息传播可导致接种规划失败,日本2013年事件使大量女性仍面临HPV相关癌症风险。
- 为解决HPV疫苗接受度问题,有必要采用良好沟通策略,多组分对话式干预似最有效,尤其当使用适合目标人群的定制语言时。
研究设计与样本
- 本文为综述,检索范围未在原文中报告。
主要发现
- 注射部位症状是报告的最常见不良事件,疼痛是最常提及的局部症状。
- 严重不良事件罕见且与严重后遗症无关,至少未发生疫苗相关死亡。
- 犹豫决定因素包括心理反应、宗教或文化方面及对脱髓鞘疾病、复杂性区域疼痛综合征(CRPS)或体位性心动过速综合征(POTS)等可能不良事件的恐惧。
- 日本2013年事件后大量女性仍易感HPV相关癌症。
关键数值与推荐
- 目前获批的三种预防性疫苗为双价HPV 16/18、四价HPV 6/11/16/18和九价HPV 6/11/16/18/31/33/45/52/58疫苗。
- 上市前和上市后研究(九价HPV疫苗尚无上市后研究)确认HPV疫苗总体安全且耐受良好。
- 多组分和对话式干预似乎最有效,尤其在使用适当语言并根据接种规划目标定制时。
临床怎么用
- 原文未据此给出推荐。
局限性
- 九价HPV疫苗尚无上市后研究。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccines stimulate a person's immune system to produce an adequate reaction against a specific infectious agent; i.e. the person is protected from that disease without having to get it first. As vaccines are administrated to healthy subjects, they are held to the highest standards of safety. Regarding human papillomavirus (HPV) vaccines, at present three prophylactic vaccines are licensed (bivalent HPV 16/18, quadrivalent HPV 6/11/16/18 and the nonovalent HPV 6/11/16/18/31/33/45/52/58 vaccine). Pre- and post-licensure studies (i.e. not yet for nonovalent HPV vaccine) confirm that HPV vaccines are generally safe and well-tolerated, site injections symptoms are the most common adverse events (AEs) reported, and pain is the most frequently referred local symptom. Serious AEs are rare and not associated with severe sequelae, at least no vaccine-related deaths have occurred. Despite these scientific evidences, it is still difficult to explain to the population the importance of a good vaccination programme. There are many determinants for HPV vaccines hesitancy which represent a barrier that must be overcome in order to increase vaccine coverage, including psychological reactions, religious or cultural aspects, and fear of possible AEs (demyelinating diseases, Complex Regional Pain Syndrome - CRPS, or Postural Orthostatic Tachycardia Syndrome - POTS). A weak communication strategy which frequently suffers due to spread of unverified news by media and websites may lead to the failure of a vaccination programme. Such a situation happened in Japan (2013), due to which a great number of women remain vulnerable to HPV-related cancers. In order to resolve the issues around HPV vaccines acceptance, it is necessary to use good communication strategies. Multicomponent and dialogue-based interventions seem to be the most effective, especially if an adequate language is used, customized according to the vaccination programme target.
引用
- Bonanni P, Zanella B, Santomauro F, et al. Safety and perception: What are the greatest enemies of HPV vaccination programmes? Vaccine. 2017. PMID: 28610824. doi:10.1016/j.vaccine.2017.05.071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。